Navigation Links
Tigris Pharmaceuticals Initiates Randomized Phase 2 Study of AFP-464 in ER-Positive Breast Cancer Patients
Date:5/26/2011

with ER positive metastatic disease."

About AFP-464

AFP-464 is a novel anti-cancer agent currently being studied by Tigris Pharmaceuticals in a randomized Phase 2 clinical trial with ER-positive breast cancer patients.  AFP-464 is also being studied by the National Cancer Institute ("NCI") under a Cooperative Research and Development Agreement (CRADA). NCI is sponsoring two  Phase 1 clinical trials in patients with solid tumors under the CRADA. Pre-clinical studies into AFP-464's mechanism of action have shown that AFP-464 is converted to metabolites, which bind covalently to DNA, resulting in p53 activation and apoptosis. AFP-464 has shown a unique pattern of growth inhibitory activity in the NCI's 60 tumor cell line screen, with breast, ovarian, lung and renal tumor cell lines exhibiting particular sensitivity to the compound. In vivo anti-tumor activity of AFP-464 has been demonstrated in several xenograft studies in mice bearing renal and breast cancer. Pre-clinical studies have shown that tumors (breast, ovarian, pancreatic and renal) with AhR localized in the cytoplasm are very sensitive to AFP-464 while those with AhR localized in the nucleus are more resistant.

About Tigris Pharmaceuticals, Inc.

Tigris Pharmaceuticals, Inc. is a privately held biopharmaceutical company that acquires, develops and commercializes innovative specialty care therapies to treat oncology, pain, inflammation, acute and supportive care areas of unmet medical need. Tigris' mission is to efficiently move its existing and future technologies through the various stages of clinical development in order to meet patients' needs for safe and effective treatments of human illnesses.

Contacts:

Alexander Mironov
Vice President of Operations
Tigris Pharmaceuticals, Inc.
(239) 444-5400
info@tigrispharma.com

This news release contains forward-loo
'/>"/>

SOURCE Tigris Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Tigris Pharmaceuticals, Inc. Completes $6.5 Million Private Placement
2. Tigris Pharmaceuticals Appoints Neil Flanzraich to Executive Chairman of the Board
3. Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute
4. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
5. Savient Pharmaceuticals Marketing Authorization Application for KRYSTEXXA® Accepted for Review by European Medicines Agency
6. Tragara Pharmaceuticals Apricoxib Reverses EMT, a Key Process for Cancer Progression and Metastasis
7. Aeolus Pharmaceuticals, Inc. to Present Live, Online at RetailInvestorConferences.com on June 2nd
8. Endo Pharmaceuticals Holdings Inc. Announces Proposed Private Offering of Senior Notes
9. Reportlinker Adds Global: Pharmaceuticals Industry Guide
10. Meta-Analyses of Phase 3 Trials Show Obese and Overweight Patients Taking Arena Pharmaceuticals Lorcaserin Achieved Statistically Significant Weight Loss
11. Amylin Pharmaceuticals Obtains Temporary Restraining Order Against Eli Lilly
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 2013  Lakeland Industries, Inc. (NASDAQ: LAKE ... industry, healthcare and to first responders on the federal, ... for the fiscal 2013 fourth quarter and year ended ... stock market close and will conduct a conference call ... (Logo: http://photos.prnewswire.com/prnh/20120611/NY21959LOGO ) The ...
(Date:5/17/2013)... DIEGO and CAMBRIDGE, Mass., May 17, 2013 /PRNewswire/ ... that a purchaser of Aveo Pharmaceutical, Inc. (NASDAQGS: AVEO) ... Court for the District of Massachusetts ... its officers violated the Securities Exchange Act of 1934 ... 1, 2013 (the "Class Period"). (Logo: ...
(Date:5/17/2013)... PHILADELPHIA , May 17, 2013 ... disorders; health economics and outcomes research also   to ... SHP, NASDAQ: SHPG ), the global specialty ... in 7 poster presentations at the American Psychiatric Association ... , May 18-22. The data being presented represent ...
Breaking Medicine Technology:Lakeland Industries to Report Fiscal Fourth Quarter and Year End Financial Results and Conduct Conference Call 2Aveo Pharmaceuticals, Inc. Sued by Investor 2Aveo Pharmaceuticals, Inc. Sued by Investor 3Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 2Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 3Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 4Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 5Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 6Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 7Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 8Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 9Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 10
... 3, 2012 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: SHP ... biotechnology research and development outsourcing company, today announced that it ... ended March 31, 2012 on May 17, 2012. Management will ... New York Time on May 17, 2012 (8:00PM Beijing Time ...
... Pharmaceuticals, Inc. (NASDAQ: OPTR ) today announced ... America Merrill Lynch 2012 Health Care Conference on Thursday, May 17 ... (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO ) A ... on the Investors page of the Company,s website at ...
Cached Medicine Technology:ShangPharma to Report First Quarter 2012 Financial Results on May 17, 2012 2
(Date:5/19/2013)... 2013 Actos lawsuit claims ... underway in U.S. District Court, Western District of Louisiana. ... 3rd, the Court has modified the litigation’s Bellwether Nomination ... rather than four. The next Status Conference in the ... (In re: Actos Product Liability Litigation, MDL No. 2299) ...
(Date:5/19/2013)... Grinding your teeth at night can ... annoying your spouse. At the same time, according to ... and Teeth Grinding Could Be a Sign of Sleep ... be hard to prevent. Apparently, Obstructive Sleep Disorder (OSD) ... its symptoms is a habit of teeth grinding along ...
(Date:5/19/2013)... 2013 These molecular diagnostics market ... Spain, Japan, Italy, Germany and France:, ... laboratory practice, as well as key economic, regulatory, ... impact during the next five years. , ... technologies, test formats, detection methodologies, trends in testing ...
(Date:5/19/2013)... York (PRWEB) May 19, 2013 The ... Case Management Conference was recently convened for hundreds of ... multidistrict litigation now underway in U.S. District Court, Southern ... the Court’s website on May 14th, the Conference addressed ... was also reported during the Conference that Defendants submitted ...
(Date:5/19/2013)... Keith Chertok now provides gum disease patients with a new ... chance of a healthier smile. Laser gum surgery ... removes diseased gum tissue in patients, but it also stimulates ... implants. , LANAP uses a laser to successfully treat ... the healthy tissue as well as encourage new bone growth. ...
Breaking Medicine News(10 mins):Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 2Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 3Health News:Dr. Kanani, Woodland Hills Dentist: Dangers of Tooth Damage and Obstructive Sleep Disorder 2Health News:Dr. Kanani, Woodland Hills Dentist: Dangers of Tooth Damage and Obstructive Sleep Disorder 3Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 2Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 3Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 4Health News:Pradaxa Lawyers at Bernstein Liebhard LLP Report on Recent Status Conference in Federal Pradaxa Litigation 2Health News:Pradaxa Lawyers at Bernstein Liebhard LLP Report on Recent Status Conference in Federal Pradaxa Litigation 3Health News:Berkeley, CA Periodontist, Dr. Keith Chertok Now Treats Gum Disease Patients With Laser Gum Surgery Prior to Placing Dental Implants 2
... Medical, Inc., a,privately held medical device company and ... announce the addition of two officers to,their management ... Finance and Chief Financial Officer. Tara Zerby joins ... "We are very excited to have Malcolm ...
... (NASDAQ: QLTI;,TSX: QLT) today announced that following a months-long business ... several,new initiatives designed to enhance shareholder value., These ... USA, Inc. whose primary assets include the Eligard(R) ... dermatology product for the treatment ...
... JOLLA, Calif., Jan. 16 Immunosyn,Corporation (OTC Bulletin ... of an Equity Research Profile on the company ... research company, nor the,associated press release announced earlier ... only authorized public and investor,relations firm retained by ...
... 17 One of Australia,s largest,pharmacy groups, Chemmart, has ... competitive threat posed by discount chains., The system ... month of,operation, participating pharmacies signed up more than 30,000 ... Results Group, has now been,rolled out to more than ...
... interventions were implemented in poor countries, cases of stunting among ... by up to a quarter, according to new research being ... of Hygiene & Tropical Medicine, is one of the authors ... Maternal and Child Undernutrition Series, which is being launched this ...
... MOUND, Texas, Jan. 16 American,HealthChoice, Inc. (Pink Sheets: ... and Tennessee, today, in an update for Company,shareholders, said ... 2007,totaled $243,000., "It was a year of positioning, ... CEO. "I am updating our shareholders on these,achievements as ...
Cached Medicine News:Health News:Cardiva Medical, Inc. Appoints Two New Officers: Malcolm Farnsworth as Vice President of Finance and Chief Financial Officer and Tara Zerby as Vice President of Business Development and Marketing 2Health News:QLT Inc. announces initial steps in strategic restructuring 2Health News:QLT Inc. announces initial steps in strategic restructuring 3Health News:QLT Inc. announces initial steps in strategic restructuring 4Health News:Equity Research Firm Issued Unauthorized Report and Press Release on Immunosyn Corporation Today 2Health News:Chemmart(R) Sees Instant Results From Launch of New Rewards Program 2Health News:One third of stunting and a quarter of deaths among under 3s in poor countries could be prevented 2Health News:American HealthChoice CEO Dr. J.W. Stucki Provides Company Update 2Health News:American HealthChoice CEO Dr. J.W. Stucki Provides Company Update 3
... Used retrograde to ... establish a Peel-Away ureteral ... The temporary protective Peel-Away ... away as the ureteroscope ...
The removable inflation/injection adapter allows the cystoscope to be removed after the catheter is in place. Supplied sterile in peel-open packages. Intended for one-time use....
Radiopaque markers are placed at the proximal and distal ends of the balloon. A special pin vise handle is included to stabilize the wire guide during introduction. Supplied sterile in peel-open pack...
Used during the performance of balloon dilation procedures to inflate and deflate the balloon and measure the pressure within the balloon during the procedure. Supplied sterile in peel-open packages....
Medicine Products: